Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)

NCT02637232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 301

Last updated 2021-05-28

Study results available
· View outcomes & findings →

Summary

The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.

Conditions

  • Rosacea

Interventions

OTHER

Mirvaso® / Onreltea TM

Sponsors & Collaborators

  • Chiltern International Inc.

    collaborator INDUSTRY
  • Galderma R&D

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02637232 on ClinicalTrials.gov